

Neehar D Parikh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5207696/nee-har-d-parikh-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144
papers

3,478
citations

30
h-index

55
g-index

165
ext. papers

5,093
ext. citations

5.5
avg. IF

6.17
L-index

#	Paper	IF	Citations
144	HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.. <i>Journal of Hepatology</i> , 2022 ,	13.4	11
143	A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation.. <i>Frontiers in Oncology</i> , 2022 , 12, 818001	5.3	1
142	Hepatocellular Carcinoma-Related Mortality in the USA, 1999-2018.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	0
141	Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	
140	Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis.. <i>JHEP Reports</i> , 2022 , 4, 100478	4.7	1
139	Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.. <i>Journal of Hepatology</i> , 2022 ,	13.4	0
138	Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1925-1932.e1	6.9	13
137	Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2379-2388.e6	6.9	2
136	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. <i>Gut</i> , 2021 , 70, 401-407	19.2	30
135	The Magnitude of the Health and Economic Impact of Increased Organ Donation on Patients With End-Stage Renal Disease.. <i>MDM Policy and Practice</i> , 2021 , 6, 23814683211063418	1.5	1
134	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021 ,	11.2	1
133	Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
132	GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis. <i>Hepatology</i> , 2021 ,	11.2	9
131	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1520-1530	6.9	12
130	Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
129	Frontiers of therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021 , 46, 3648-3659	3	3
128	A Panel of Glycopeptides as Candidate Biomarkers for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. <i>Journal of Proteome Research</i> , 2021 , 20, 3278-3289	5.6	8

127	Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. <i>Hepatology Communications</i> , 2021 , 5, 1481-1489	6	4
126	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021 , 46, 3625-3633	3	1
125	Management of early hepatocellular carcinoma: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. <i>Hpb</i> , 2021 , 23, 753-761	3.8	1
124	Radiation Therapies for the Treatment of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021 , 17, 341-346	3.6	2
123	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	10
122	REPLY. <i>Hepatology</i> , 2021 , 74, 1715	11.2	
121	A machine learning approach for the prediction of overall deceased donor organ yield. <i>Surgery</i> , 2021 , 170, 1561-1567	3.6	
120	Oral simethicone tablets with PEG-ELS split-prep reduces frequency of inadequate bowel cleansing and decreases bubbles. <i>GastroHep</i> , 2021 , 3, 254-260	1	
119	Alcohol Policies and Alcohol-related Liver Disease Mortality. <i>Gastroenterology</i> , 2021 , 161, 350-352	13.3	1
118	The Future of Quality Improvement for Cirrhosis. <i>Liver Transplantation</i> , 2021 , 27, 1479-1489	4.5	1
117	Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2021 , 73, 713-725	11.2	50
116	Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 212-219	4	4
115	Assessment of National Organ Donation Rates and Organ Procurement Organization Metrics. <i>JAMA Surgery</i> , 2021 , 156, 173-180	5.4	4
114	Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales. <i>Alcoholism: Clinical and Experimental Research</i> , 2021 , 45, 51-53	3.7	
113	Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 604-606.e1	6.9	11
112	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 4508-4517	4	1
111	TNFR1 and the TNF α axis as a targetable mediator of liver injury from stereotactic body radiation therapy. <i>Translational Oncology</i> , 2021 , 14, 100950	4.9	4
110	Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11

109	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021 , 2, 836-850.e10	31.7	3
108	Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. <i>Gastroenterology</i> , 2021 , 161, 1502-1512	13.3	3
107	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
106	PRM-MS Quantitative Analysis of Isomeric -Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma. <i>Metabolites</i> , 2021 , 11,	5.6	5
105	Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 890-901	6.1	7
104	Falls are common, morbid, and predictable in patients with cirrhosis. <i>Journal of Hepatology</i> , 2021 , 75, 582-588	13.4	6
103	Recent Advances in Hepatocellular Carcinoma Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2020-2024	6.9	2
102	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 343-352	2.1	5
101	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021 , 5, 538-547	6	1
100	Risk of Hepatocellular Carcinoma in Patients with Indeterminate (LI-RADS 3) Liver Observations.. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
99	Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1397-1405	6.1	19
98	Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis. <i>Journal of Proteome Research</i> , 2020 , 19, 3452-3466	5.6	21
97	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020 , 72, 1654-1665	11.2	56
96	Reply. <i>Gastroenterology</i> , 2020 , 158, 1844	13.3	
95	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. <i>Liver International</i> , 2020 , 40, 947-955	7.9	10
94	Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2879-2902.e9	6.9	18
93	Biomarkers for the Early Detection of Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2495-2503	4	32
92	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1642-1649	0.7	17

91	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1197-1206.e7	6.9	12
90	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	17
89	EUS-guided gastrojejunal anastomosis to facilitate endoscopic retrograde cholangiography in a patient with a right lobe liver transplant and Roux-en-Y anatomy. <i>VideoGIE</i> , 2020 , 5, 473-475	1.1	2
88	Comprehensive Health-State Utilities in Contemporary Patients With Cirrhosis. <i>Hepatology Communications</i> , 2020 , 4, 852-858	6	2
87	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. <i>Scientific Reports</i> , 2020 , 10, 20922	4.9	9
86	Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020 , 115, 2017-2025	0.7	20
85	#LiverTwitter: An Emerging Tool for Liver Education and Research. <i>Hepatology Communications</i> , 2020 , 4, 1229-1233	6	9
84	Author response to Letter to the Editor: Chronological change in alpha-fetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus. <i>Liver International</i> , 2020 , 40, 2307	7.9	
83	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020 , 12,	6.6	1
82	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. <i>Hepatology</i> , 2020 , 71, 225-234	11.2	17
81	Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 217-226	1.6	7
80	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 974-983	6.9	12
79	Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. <i>Pharmacoeconomics</i> , 2020 , 38, 5-24	4.4	6
78	Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1669-1678	4	9
77	Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. <i>Abdominal Radiology</i> , 2020 , 45, 3698-3708	3	9
76	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019 , 157, 1253-1263.e2	13.3	77
75	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019 , 156, 1683-1692.e1	13.3	79
74	Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. <i>Clinical Liver Disease</i> , 2019 , 13, 13-19	2.2	22

73	Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 976-987.e4	6.9	51
72	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 551-559.e1	6.9	81
71	Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. <i>Scientific Reports</i> , 2019 , 9, 11580	4.9	9
70	Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. <i>Clinical Diabetes and Endocrinology</i> , 2019 , 5, 9	4.7	11
69	Estimated Association Between Organ Availability and Presumed Consent in Solid Organ Transplant. <i>JAMA Network Open</i> , 2019 , 2, e1912431	10.4	9
68	Liquid Biopsy for Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2019 , 18, 390-399	1	1
67	Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis. <i>Hepatology Communications</i> , 2019 , 3, 1510-1519	6	31
66	Hepatocellular Carcinoma Surveillance and Staging. <i>Molecular and Translational Medicine</i> , 2019 , 27-51	0.4	2
65	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1228-1238	6.9	22
64	New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019 , 9, 18575	4.9	18
63	Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures: An Analysis of the Nationwide Inpatient Sample. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, e356-e361	3	2
62	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. <i>Liver Transplantation</i> , 2019 , 25, 369-379	4.5	22
61	Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches. <i>Mass Spectrometry Reviews</i> , 2019 , 38, 265-290	11	40
60	Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 766-773	6.9	38
59	Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis. <i>Hepatology</i> , 2019 , 69, 1676-1685	11.2	34
58	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute@ Early Detection Research Network. <i>Contemporary Clinical Trials</i> , 2019 , 76, 49-54	2.3	8
57	Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. <i>Hepatology</i> , 2019 , 70, 487-495	11.2	69
56	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. <i>Gastroenterology</i> , 2018 , 154, 1706-1718.e1	13.3	352

55	Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. <i>American Journal of Gastroenterology</i> , 2018 , 113, 529-538	0.7	26
54	A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. <i>Hepatology</i> , 2018 , 68, 1498-1507	11.2	41
53	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 198-210.e2	6.9	143
52	A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 781-782	6.9	11
51	Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 122-130	4	76
50	Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. <i>BMJ, The</i> , 2018 , 362, k2817	5.9	317
49	Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018 , 62, 673-681	1.7	19
48	Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Cancer Research and Treatment</i> , 2018 , 50, 530-537	5.2	13
47	Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 40-47	13.4	90
46	Development of a Predictive Model for Deceased Donor Organ Yield. <i>Transplantation</i> , 2018 , 102, e364	1.8	1
45	Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 127-137	6.1	44
44	Radiologist Quality Assurance by Nonradiologists at Tumor Board. <i>Journal of the American College of Radiology</i> , 2018 , 15, 1259-1265	3.5	10
43	Predictors of Deceased Donor Kidney Discard in the United States. <i>Transplantation</i> , 2017 , 101, 1690-1697	7.8	41
42	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. <i>American Journal of Medicine</i> , 2017 , 130, 1099-1106.e1	2.4	73
41	Changes in Liver Transplant Criteria for Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2017 , 16, 33-38	1	
40	Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. <i>Current Treatment Options in Gastroenterology</i> , 2017 , 15, 296-304	2.5	21
39	Reply. <i>Hepatology</i> , 2017 , 66, 1002-1003	11.2	2
38	Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 3243-3253	4	11

37	Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 451-459	5.6	20
36	Reply. <i>Hepatology</i> , 2017 , 66, 679-680	11.2	
35	Population-Based Analysis and Projections of Liver Supply Under Redistricting. <i>Transplantation</i> , 2017 , 101, 2048-2055	1.8	8
34	Biomarker development for hepatocellular carcinoma early detection: current and future perspectives. <i>Hepatic Oncology</i> , 2017 , 4, 111-122	4	35
33	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2017 , 123, 3725-3731	6.4	51
32	Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 169-177	6.1	135
31	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. <i>Hepatology</i> , 2017 , 65, 122-133	11.2	65
30	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017 , 65, 1196-1205	11.2	123
29	Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. <i>Hepatology</i> , 2017 , 65, 875-884	11.2	86
28	ANOVA models for Brownian motion. <i>Communications in Statistics - Theory and Methods</i> , 2017 , 46, 7642-7650		
27	Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017 , 37, 296-304	7.3	18
26	PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1632-1633	0.7	1
25	Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 452-452	2.2	
24	Reinterpretation of Outside Hospital MRI Abdomen Examinations in Patients With Cirrhosis: Is the OPTN Mandate Necessary?. <i>American Journal of Roentgenology</i> , 2016 , 207, 782-788	5.4	12
23	Controversies in criteria for liver transplantation in hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2016 , 32, 182-8	3	6
22	INPATIENT HYPOGLYCEMIC EVENTS IN A COMPARATIVE EFFECTIVENESS TRIAL FOR GLYCEMIC CONTROL IN A HIGH-RISK POPULATION. <i>Endocrine Practice</i> , 2016 , 22, 1040-7	3.2	5
21	Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients. <i>Liver Transplantation</i> , 2016 , 22, 1092-8	4.5	24
20	Stereotactic body radiotherapy (SBRT) as an alternative to transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4087-4087	2.2	1

19	Phase II study of individualized adaptive stereotactic body radiotherapy (SBRT) for patients at high risk for liver damage.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 424-424	2.2	2
18	The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016 , 13, e1002005	11.6	4
17	Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2016 , 7, 97-100	2.2	16
16	Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2016 , 7, e172	4.2	16
15	Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. <i>Liver Transplantation</i> , 2015 , 21, 1142-52	4.5	139
14	Projections in donor organs available for liver transplantation in the United States: 2014-2025. <i>Liver Transplantation</i> , 2015 , 21, 855-63	4.5	26
13	Clinical outcomes and quality of life in recipients of livers donated after cardiac death. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 680316	2	5
12	Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes. <i>Annals of Hepatology</i> , 2014 , 13, 548-554	3.1	2
11	Response to Sage and Mogrovejo. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1688-9	0.7	
10	Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014 , 28, 1668-73	5.2	30
9	Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes. <i>Annals of Hepatology</i> , 2014 , 13, 548-54	3.1	0
8	A colorectal cancer screening program in an underserved, ethnically diverse population in Chicago, IL. <i>Journal of Community Health</i> , 2013 , 38, 603-8	4	2
7	A cost-efficacy decision analysis of prophylactic clip placement after endoscopic removal of large polyps. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1319-24	6.9	50
6	Hepatotoxicity and drug interactions in liver transplant candidates and recipients. <i>Clinics in Liver Disease</i> , 2013 , 17, 737-47, x-xi	4.6	7
5	Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). <i>Cancer</i> , 2012 , 118, 5997-6004	6.4	16
4	Quality of life, risk assessment, and safety research in liver transplantation: new frontiers in health services and outcomes research. <i>Current Opinion in Organ Transplantation</i> , 2012 , 17, 241-7	2.5	14
3	Glycemic control by a glucose management service and infection rates after liver transplantation. <i>Endocrine Practice</i> , 2011 , 17, 546-51	3.2	28
2	Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. <i>Transplantation</i> , 2010 , 89, 222-6	1.8	59

1	Glycopeptides with Sialyl Lewis Antigen in Serum Haptoglobin as Candidate Biomarkers for Nonalcoholic Steatohepatitis Hepatocellular Carcinoma Using a Higher-Energy Collision-Induced Dissociation Parallel Reaction Monitoring-Mass Spectrometry Method. <i>ACS Omega</i> ,	3.9	1
---	---	-----	---